Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Peptides. 2010 Sep 15;31(12):2304–2313. doi: 10.1016/j.peptides.2010.08.025

Table 1.

Functional activity of the modified peptides at the mouse melanocortin receptors

mMC1R mMC3R mMC4R mMC5R hMC5R

Peptide Structure EC50 (nM) EC50 (nM) EC50 (nM) EC50 (nM) EC50 (nM)
α-MSH Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 0.70±0.23 2.10±0.46 2.6±0.29 2.00±0.20
NDP-MSH Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH2 1.0±0.78 0.09±0.02 0.10±0.01 0.22±0.03 0.53±0.10
γ2-MSH
(Bachem control)
 Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly 680±190 38±6.5 420±68 42±14 2700±900
1 γ2-MSH  Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly 690±260 51±5.3 580±160 73±14 2600±620
2  Tyr-Val-Met-Gly-His-Phe-Arg-DTrp8-Asp-Arg-Phe-Gly 120±44 90±46 5580±2300 48±20 580±280
3  Tyr-Val-Nle3-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly 390±90 68±30 270±82 140±80 1900±620
4  Tyr-Val-Nle3-Gly-His-Phe-Arg-DTrp8-Asp-Arg-Phe-Gly 31±11 40±20 94±33 10±1.7 210±58
5  Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe (1-11) 1500±90 160±10 1100±78 130±52 2010±460
6  Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg (1-10) 250±60 36±9.2 660±190 62±23 7360±2300
7  Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp (1-9) 430±90 800±96 1380±470 73±17 4455±1510
8  Tyr-Val-Met-Gly-His-Phe-Arg-Trp (1-8) 2900±960 2800±950 4200±590 710±160 23900±8600
9  Tyr-Val-Met-Gly-His-Phe-Arg- (1-7) 28100±6700 31600±2100 >100000 2360±13600 >100000
10  Tyr-Val-Met-Gly-His-Phe (1-6) >100000 >100000 >100000 >100000 >100000
11  Tyr-Val-Met-Gly-His (1-5) 60%@100μM >100000 25%@100μM 26800±3400
12  Tyr-Val-Met-Gly (1-4) >100000 >100000 >100000 >100000
13  Tyr-Val-Met-OH (1-3) >100000 >100000 >100000 >100000
14 Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly (2-12) 1260±480 400±250 830±350 81±32
15 Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly (3-12) 1590±520 260±67 1200±460 94±14
16 Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly (4-12) 7860±2650 760±240 2700±550 290±150
17 His-Phe-Arg-Trp-Asp-Arg-Phe-Gly (5-12) 20100±5900 2670±100 8380±2700 760±290
18 Phe-Arg-Trp-Asp-Arg-Phe-Gly (6-12) 30%@100μM >100000 47400±17700 13500±7200
90%@100μM
19 Arg-Trp-Asp-Arg-Phe-Gly (7-12) >100000 >100000 >100000 >100000
20 Trp-Asp-Arg-Phe-Gly (8-12) >100000 >100000 >100000 >100000
21 Asp-Arg-Phe-Gly (9-12) >100000 >100000 >100000 >100000
22 Arg-Phe-Gly (10-12) >100000 >100000 >100000 >100000
23    Tyr-Met-His-Phe-Arg-Trp-Phe (1,3,5-8,11) 67100±1110 10400±2250 14010±3700 1100±280
24    Met-Gly-His-Phe-Arg-Trp (3-8) 14500±2100 22400±5200 41900±11800 4430±3800
25 His-Phe-Arg-Trp-Asp-Arg-Phe (5-11)    44800±6100 6600±700 64400±19800 1870±620
26 Phe-Arg-Trp-Asp-Arg-Phe (6-11)    3170±750 20400±3300 34040±9500 6730±1490
27 Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe (3-11)    1770±270 365±90 2410±860 100±23
28 Asp-Arg-Phe (9-11)    >100000 >100000 >100000 >100000
29 His-Phe-Arg-Trp (5-8) >100000 >100000 >100000 10100±330
85%@100μM
>100000

The indicated errors represent the standard error of the mean determined from at least three independent experiments. >100,000 indicates that agonist or antagonist activity was not observed for these compounds at up to 100μM concentrations. A percentage value indicates that some stimulatory agonist pharmacology resulted at up to 100 μM concentrations, but the maximal stimulation levels were less then the 100% control level of NDP-MSH.